


Cell Line Designation	LIM2551
CellBank Catalogue No.	CBA-0170
Lot Number	01700910E
Passage Number	14
Total Cell Number	2-4x 10 ⁶ cells
Expected Cell Viability	92%
Brief Description	Cell line derived from an adenocarcinoma of the transverse colon
Organism	Human (<i>Homo Sapiens</i>)
Tissue	Colon
Growth Properties	Grows as loose aggregates of small rounded cells, some adherent, others in suspension
Morphology	Epithelial

Image



Growth Medium	RPMI1640 (with 2mM L-Glutamine + 25mMHepes)+10%FCS, Insulin 0.6µg/ml, Hydrocortisone 1µg/ml, 1-Thioglycerol 10µM
Subcultivation Ratio	Split sub confluent flasks (70-80%). Optimal split ratio 1:8-1:16 using 0.05%Trypsin/EDTA at 37°C for 5 minutes. Seeding density 1.0x10 ⁴ cells/cm ²

**Establishing and
Maintaining your Culture**

Cells maintained at 37°C and 5% CO₂. LIM2551 requires growth medium to be changed 3 times each week. Feed and passage as for semi-adherent culture (collect medium with floating cells and then trypsinise the adherent population, pool both together before reseeding).

Refer to Technical & Customer Service Information pamphlet for further information

Cryoprotectant Medium

10% DMSO + 90% FCS

Biosafety level

Cell line of human origin. CellBank Australia recommends that cell lines be handled at category PC-2* containment level.

*AS/NZS 2243.3:2010

Use Restrictions

These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).

Safety Precaution

Where cell lines are shipped as frozen ampoules there is a small risk that the ampoule may be pressurised, due to the expansion of trapped liquid nitrogen and could explode on warming. It is recommended that persons handling ampoules of frozen cells wear appropriate personal protective equipment including laboratory coat, insulated gloves and a full protective face shield.

**Handling Procedure for
Frozen Cells**

Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability. Remove protective cryoflex layer around the ampoule prior to thawing. A precentrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.

Additional Information

HNPCC patient, mutations in p53 (wt/stop at aa 49), beta-catenin (delta aa A5 to A76), B-Raf (aa V600E), MSI, A33 negative

Depositor

Professor Tony Burgess
Ludwig Institute for Cancer Research Ltd, Melbourne
Australia

References

Zhang H. *et al.* Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf
Int.J.Cancer 2009 July 15; 125(2):297-307

CellBank Warranty

While CellBank Australia uses reasonable efforts to include accurate and up-to date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.

Disclaimers

This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures.

Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com